https://marketchameleon.com/articles/b/2026/10/26/meta-launches-35b-financing-plan-mandatory-convertible-forward-sale 2026-10-26T07:08:28.4338800-04:00 0.9 Market Chameleon en 2026-10-26T07:08:28.4338800-04:00 Meta Launches a $35B Two-Part Financing Plan as It Targets $135–$145B in 2026 Capex $META, #Premarket, #StockMovers https://marketchameleon.com/articles/b/2026/10/26/iova-esmo-2026-lifileucel-durable-responses-soft-tissue-sarcomas-saratoga 2026-10-26T07:07:55.4927810-04:00 0.9 Market Chameleon en 2026-10-26T07:07:55.4927810-04:00 Iovance spotlights 50% response rate for lifileucel in early soft tissue sarcoma pilot as SARATOGA registrational trial enrolls $IOVA, #Premarket, #StockMovers https://marketchameleon.com/articles/b/2026/10/26/teck-highland-valley-copper-strike-reduced-capacity-update 2026-10-26T07:07:32.8050000-04:00 0.9 Market Chameleon en 2026-10-26T07:07:32.8050000-04:00 Teck flags Highland Valley Copper strike as operations run at reduced capacity $TECK, #Premarket, #StockMovers https://marketchameleon.com/articles/b/2026/10/26/bntx-dynasty-breast02-phase-3-topline-pfs-modest-ild 2026-10-26T07:07:16.9221110-04:00 0.9 Market Chameleon en 2026-10-26T07:07:16.9221110-04:00 BioNTech’s DYNASTY-Breast02 Phase 3 readout hits PFS endpoint, but companies flag “limited” benefit and higher ILD rates $BNTX, #Premarket, #StockMovers https://marketchameleon.com/articles/b/2026/10/26/gmab-phase-2-updated-data-28-2-month-median-overall-survival-petosemtamab-pembrolizumab-hnscc 2026-10-26T07:06:56.7572030-04:00 0.9 Market Chameleon en 2026-10-26T07:06:56.7572030-04:00 Genmab Highlights 28.2-Month Median Overall Survival in Phase 2 Petosemtamab Plus Pembrolizumab Data for First-Line r/m HNSCC $GMAB, #Premarket, #StockMovers https://marketchameleon.com/articles/b/2026/10/26/eqt-range-resources-all-stock-acquisition-natural-gas-champion 2026-10-26T07:06:34.5368410-04:00 0.9 Market Chameleon en 2026-10-26T07:06:34.5368410-04:00 EQT targets >$50B pro forma enterprise value in all-stock deal for Range Resources $EQT, #Premarket, #StockMovers https://marketchameleon.com/articles/b/2026/10/26/rrc-eqt-acquisition-all-stock-exchange-ratio-0-987 2026-10-26T07:06:11.7540190-04:00 0.9 Market Chameleon en 2026-10-26T07:06:11.7540190-04:00 Range Resources (RRC) in Focus as EQT Offers 0.987 Shares per RRC in All-Stock Deal $RRC, #Premarket, #StockMovers https://marketchameleon.com/articles/b/2026/10/26/apxc-nasdaq-listing-ads-offering-rift-rare-earth-drilling 2026-10-26T07:05:48.3906420-04:00 0.9 Market Chameleon en 2026-10-26T07:05:48.3906420-04:00 Apex Critical Metals Joins Nasdaq After $1.86 Million ADS Offering to Fund Rift Rare Earth Drilling $APXC, #Premarket, #StockMovers https://marketchameleon.com/articles/b/2026/10/26/nu-cto-transition-ceo-oversees-global-platforms-through-2026 2026-10-26T07:05:26.3403580-04:00 0.9 Market Chameleon en 2026-10-26T07:05:26.3403580-04:00 Nu Holdings sets a long runway for CTO transition as CEO David Vlez takes interim oversight through Nov. 12, 2026 $NU, #Premarket, #StockMovers https://marketchameleon.com/articles/i/2026/10/23/32048-why-selling-this-iron-condor-spread-in-soxl-makes- 2026-10-23T15:29:22.2798980-04:00 0.9 https://marketchameleon.com/articles/i/2026/10/23/32047-why-this-xle-bull-put-spread-makes-sense-for-0-65 2026-10-23T15:00:51.9103230-04:00 0.9 https://marketchameleon.com/articles/i/2026/10/23/32046-ewz-bullish-option-set-up-with-5pct-downside-cushion 2026-10-23T14:19:24.5461330-04:00 0.9 https://marketchameleon.com/articles/i/2026/10/23/32045-why-selling-this-iron-condor-in-mdb-makes-sense-fo 2026-10-23T14:08:31.8066720-04:00 0.9 https://marketchameleon.com/articles/i/2026/10/23/32044-3-reasons-why-this-ewz-bull-put-spread-is-a-good-o 2026-10-23T14:00:48.5115160-04:00 0.9 https://marketchameleon.com/articles/i/2026/10/23/32043-how-this-uso-put-spread-could-make-33pct-in-20-days 2026-10-23T12:05:07.7846700-04:00 0.9 https://marketchameleon.com/articles/i/2026/10/23/32042-how-to-make-14pct-roi-with-qqq-put-spread 2026-10-23T12:05:07.6285520-04:00 0.9